Skip to main content
. 2015 Sep 16;6:8323. doi: 10.1038/ncomms9323

Figure 1. Correlation of GR expression with pharmacotherapy resistance of breast cancer cells and clinical outcomes of breast cancer patients.

Figure 1

(a) Correlation of GR expression with resistance to the mammalian target of rapamycin inhibitor AZD8055, AKT inhibitor MK2206 and mitotic kinesin Eg5 inhibitor S-trityl-L-cysteine in multiple breast cancer cell lines. The numbers in the brackets indicate the numbers of different breast cancer cell lines. The gene expression data are from a previous study12. (b) Kaplan–Meier analysis comparing overall survival of a cohort of TNBC patients distinguished by low versus high expression of the GR gene. The clinical gene expression data are from a previous study14. (c) Kaplan–Meier curves comparing distant metastasis-free survival of another cohort of TNBC patients undergoing chemotherapy distinguished by low versus high expression of the GR gene. The clinical gene expression data are from a previous study15.